ARTICLE | Company News
Merck sales and marketing update
October 26, 2015 7:00 AM UTC
The U.K.’s NICE issued a final appraisal determination (FAD) recommending the use of Keytruda pembrolizumab as first-line treatment of advanced melanoma. The FAD is contingent on Merck providing Keyt...